Glucotrack (Nasdaq:GCK) announced today that it completed the first preclinical study of its implantable continuous blood glucose monitor (CBGM).
Rutherford, New Jersey-based Glucotrack aimed to assess the implant technique and device safety in the study. Additionally, the study used a small sample size of sensors to determine device functionality.
Despite no intent to conduct an accuracy study, the company reported a mean absolute relative difference (MARD) of 8.1% at day 30 and 4.5% at day 60. Glucotrack reported no significant adverse events.
Get the full story at our sister site, Drug Delivery Business News.